Home    Back

96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004387-72-AT
(EUCTR)		11/10/200509/06/2005A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/AA Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A Crohn’s disease (CD) in patients with at least one perianal fistula.
MedDRA version: 7.1;Level: LLT;Classification code 10011401		Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody		Protein Design Labs, Inc.NULLNot RecruitingFemale: yes
Male: yes		18Phase 2aAustria;Germany
2EUCTR2004-004387-72-DE
(EUCTR)		03/06/200507/01/2005A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/AA Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A Crohn’s disease (CD) in patients with at least one perianal fistula.
MedDRA version: 7.1;Level: LLT;Classification code 10011401		Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody		PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes		18Phase 2aGermany
3EUCTR2004-004388-31-DE
(EUCTR)		03/06/200507/01/2005A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/AA Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/A Moderate-to-severe inflammatory, nonstricturing, nonpenetrating Crohn’s disease (CD).
MedDRA version: 7.1;Level: LLT;Classification code 10011401		Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody		PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes		18Phase 2aGermany
4NCT00267709
(ClinicalTrials.gov)		February 200519/12/2005Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseA Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's DiseaseCrohn's DiseaseDrug: VisilizumabFacet BiotechPDL BioPharma, Inc.Completed18 Years70 YearsBoth18Phase 2United States
5NCT00267722
(ClinicalTrials.gov)		February 200519/12/2005Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseA Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's DiseaseCrohn's DiseaseDrug: VisilizumabFacet BiotechPDL BioPharma, Inc.Completed18 Years70 YearsBoth18Phase 2United States

Back to top